<i>Tech across New England: </i>NanoViricides leads disarming of viral infections

Tue, 08/31/2010 - 8:33pm
Mass High Tech: The Journal of New England Technology

NanoViricides Inc.

Location: West Haven, Conn.


Phone: 203-937-6137

Founded: 2005

top Executive: Eugene Seymour, CEO

Industry: Anti-viral therapeutics

NanoViricides Inc. is a development-stage, nano-biopharmaceutical company discovering, developing, and commercializing nanotechnology-based targeted anti-viral therapeutics (nanoviricides) to advance the care of patients suffering from life-threatening viral infections. The company’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and dismantle them. The company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.

Increasingly virulent, drug-resistant, easily-transmissible, mutant viruses continue to be a significant challenge that has led to the use of “cocktail” therapies with associated side-effect and drug interaction concerns.  NanoViricide’s work is exciting because, unlike some other therapeutic solutions, their technology shows no sign of toxicity so far in preliminary safety studies – the material used is non-toxic and biodegradable. Even more promising, nanoviricides destroy viruses, not merely slow them down.

Last month, the company reported that its anti-Herpes drug candidate showed significant efficacy in cell culture studies.

From the top, CEO Eugene Seymour: “We have a platform technology that enables us to rapidly create anti-viral agents that specifically target a wide spectrum of viruses. We have nanoviricides that have shown efficacy against more common viral diseases such as herpes, HIV, and influenza as well such viral diseases as epidemic keratoconjunctivitis (EKC), dengue, and Ebola, for which there are no currently-approved therapeutics. We’re moving as quickly as possible to file a pre-IND with the FDA for the first of our drug candidates.”




Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.